Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


Harjes Thesis.pdf (377.76 KB)

ETD Abstract Container

Abstract Header

Fibroblast growth factor-23 in canine chronic kidney disease

Harjes, Laura
http://rave.ohiolink.edu/etdc/view?acc_num=osu1492430281592083

Abstract Details

2017, Master of Science, Ohio State University, Comparative and Veterinary Medicine.
Chronic kidney disease (CKD) is associated with hyperphosphatemia, reduced vitamin D metabolite concentrations, and hyperparathyroidism. This syndrome is known as CKD-mineral and bone disorder (CKD-MBD). Recently it has been shown that increased fibroblast growth factor-23 (FGF23) concentration is one of the earliest biomarkers of CKD in people and cats. It is an independent risk factor for both progression of kidney disease and survival time in humans and cats. FGF23 information in healthy and CKD dogs is lacking. The primary objective of this study was to measure FGF23 concentration in dogs with different stages of CKD and to determine its association with factors involved in CKD-MBD, including phosphate and parathyroid hormone (PTH) concentrations. A secondary aim was to validate an ELISA for measurement of canine plasma FGF23. Thirty-two client-owned dogs with naturally occurring CKD and 10 healthy control dogs were enrolled in this prospective cross-sectional study. A human FGF23 ELISA was used to measure plasma FGF23 and its association with creatinine, phosphate, calcium, and PTH was determined. Plasma FGF23 concentration increased with severity of kidney disease and was significantly different between IRIS stages 1 and 2 versus stages 3 and 4 (P <0.0001). Increased plasma FGF23 concentration occurred more frequently than hyperparathyroidism or hyperphosphatemia in this cohort. Serum creatinine and phosphate concentrations were the strongest independent predictors of FGF23 concentration. Plasma FGF23 concentration increased in CKD dogs as disease progressed. Plasma FGF23 concentration appears to be useful for further study of the pathophysiology of canine CKD-MBD.
Valerie Parker (Advisor)
Ramiro Toribio (Committee Member)
Catherine Langston (Committee Member)
Dennis Chew (Committee Member)
49 p.
Veterinary Services
canine chronic kidney disease; Fibroblast growth factor 23; phosphate and parathyroid hormone concentrations

Recommended Citations

Citations

  • Harjes, L. (2017). Fibroblast growth factor-23 in canine chronic kidney disease [Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1492430281592083

    APA Style (7th edition)

  • Harjes, Laura. Fibroblast growth factor-23 in canine chronic kidney disease. 2017. Ohio State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=osu1492430281592083.

    MLA Style (8th edition)

  • Harjes, Laura. "Fibroblast growth factor-23 in canine chronic kidney disease." Master's thesis, Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1492430281592083

    Chicago Manual of Style (17th edition)

osu1492430281592083
725
© 2017, all rights reserved.
This open access ETD is published by The Ohio State University and OhioLINK.
Release 3.2.12